Mingkun Chen
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
FOXQ1 activates GLT8D2 to enhance CCL2 N-glycosylation and promote prostate cancer bone metastasis.
Journal: Cell death & disease
Published: January 06, 2026
Gasless single-port retroperitoneal laparoscopic adrenalectomy: a novel option for adrenal tumors.
Journal: Translational andrology and urology
Published: December 11, 2025
A risk prediction model for prognosis and immunotherapy response in prostate cancer patients based on immunosuppressive neutrophil Neu_2 subsets
Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University
Published: September 08, 2025
Correction: ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer.
Journal: Frontiers in cell and developmental biology
Published: June 13, 2025
ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer.
Journal: Frontiers in cell and developmental biology
Published: March 23, 2025
BioBERT-powered synergy: advanced bibliometric and molecular insights into prostate cancer bone metastasis.
Journal: Frontiers in immunology
Published: January 17, 2025
Tegaserod maleate exerts anti-tumor effects on prostate cancer via repressing sonic hedgehog signaling pathway.
Journal: Molecular medicine (Cambridge, Mass.)
Published: November 13, 2024
BOOST: a robust ten-fold expansion method on hour-scale.
Journal: Nature communications
Published: July 19, 2024
Perivesical Fat Invasive Pattern as Prognostic Factor and Predictor of Response to Adjuvant Chemotherapy in T3 Stage Bladder Cancer.
Journal: Clinical genitourinary cancer
Published: December 04, 2022
ACO1 and IREB2 downregulation confer poor prognosis and correlate with autophagy-related ferroptosis and immune infiltration in KIRC.
Journal: Frontiers in oncology
Published: April 27, 2022
Complete transurethral resection of bladder tumor before radical cystectomy is not a risk factor for organ-confined bladder cancer: A case-control study.
Journal: Current urology
Published: December 19, 2021
Activating transcription factor 5 (ATF5) promotes tumorigenic capability and activates the Wnt/b-catenin pathway in bladder cancer.
Journal: Cancer cell international
Published: September 07, 2021
Last Updated: 09/26/2026